Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

ABSTRACT:

SUBMITTER: Johnston SRD 

PROVIDER: S-EPMC11200328 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature